- £14.96m
- £14.66m
- £2.45m
REG - EMV Capital PLC - Preliminary results for the year ended 31 Dec 2024
AnnouncementREG - EMV Capital PLC - PDS: Q1 Results and Clinical and Corporate Update
AnnouncementREG - EMV Capital PLC - TR-1
AnnouncementREG - EMV Capital PLC - PDS: Q4 Results and Clinical Programs Update
AnnouncementREG - EMV Capital PLC - PDS: VERSATILE-003 Phase 3 Clinical Trial
AnnouncementREG - EMV Capital PLC - PDS: up to $22mn Registered Direct Offering
AnnouncementREG - EMV Capital PLC - PDS Biotech reaffirms guidance for clinical trial
AnnouncementREG - EMV Capital PLC - ProAxsis: Status Update and Proposed Fundraise
AnnouncementREG - EMV Capital PLC - TR-1
AnnouncementREG - EMV Capital PLC - Grant of Share Options
AnnouncementREG - EMV Capital PLC - Q-Bot Fundraising
AnnouncementREG - EMV Capital PLC - TR-1
AnnouncementREG - EMV Capital PLC - Wanda Health Fundraising
AnnouncementREG - EMV Capital PLC - Close of Fundraising and Result of Retail Offer
AnnouncementREG - EMV Capital PLC - Result of Subscription
AnnouncementREG - EMV Capital PLC - WRAP Retail Offer
AnnouncementREG - EMV Capital PLC - Proposed Subscription and Retail Offer; Update
AnnouncementREG - EMV Capital PLC - PDS: Clinical Programs Update, 3rd Quarter Results
AnnouncementREG - EMV Capital PLC - Director/PDMR Shareholding
Announcement